Welcome to our dedicated page for AdaptHealth SEC filings (Ticker: AHCO), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
AdaptHealth Corp. filings document the company’s healthcare-at-home operations, financial reporting and public-company governance. Its Form 8-K disclosures include quarterly and annual earnings releases, Regulation FD updates, financial guidance, business highlights and material events related to operating partnerships, asset dispositions and executive leadership changes.
The filing record also covers capital structure and financing matters, including credit agreements entered into by AdaptHealth LLC and related guarantees, collateral and borrowing commitments. AdaptHealth’s proxy materials describe board and executive compensation matters, while its securities disclosures identify common stock trading under AHCO on the Nasdaq Stock Market.
AdaptHealth Corp. received an updated ownership filing from One Equity Partners–affiliated entities and Richard Cashin. This Amendment No. 4 to a Schedule 13D reports that the group of “Reporting Persons” may be deemed to beneficially own 15,864,871 shares of AdaptHealth common stock.
The filing states this position represents approximately 11.7% of the company’s common stock, based on 135,914,816 shares outstanding as of February 20, 2026, as reported in AdaptHealth’s Form 10-K. The shares are directly held by OEP AHCO Investment Holdings, LLC, which is owned by several Parallel Funds managed through OEP VII General Partner, L.P. and OEP VII GP, L.L.C.
The six-member investment committee of OEP VII GP, whose majority must include Richard Cashin, exercises voting and investment discretion over the reported securities, though the filing clarifies that no Reporting Person admits beneficial ownership for any other legal purpose. The group also notes that, within the prior 60 days, they acquired AdaptHealth shares in market transactions listed in an attached exhibit.
AdaptHealth Corp. director Susan T. Weaver reported a bona fide gift of 73,472 shares of AdaptHealth common stock, transferred to the Susan T. Weaver 2025 Irrevocable Trust for the benefit of her spouse and children. The filing lists the transaction as a gift transfer with no sale price.
After these transactions, Weaver directly holds 21,346 shares of AdaptHealth common stock and indirectly holds 73,472 shares through the irrevocable trust, reflecting a shift of ownership to a family estate-planning vehicle rather than a market sale.
AdaptHealth Corp. director Dale B. Wolf reported an open-market purchase of common stock. On February 27, 2026, he bought 8,000 shares of AdaptHealth common stock at a weighted average price of $8.96 per share.
After this transaction, Wolf directly owned 104,235 common shares. The filing also reports an additional 14,000 common shares held indirectly by a trust, reflecting indirect ownership separate from his direct holdings.
AdaptHealth Corp. insider Richard W. Rew II, the company’s CLO and General Counsel, reported an open-market purchase of 5,000 shares of common stock at $8.91 per share. Following this Form 4 transaction, his directly owned AdaptHealth shareholdings increased to 107,097 shares.
AdaptHealth Corp. filed its annual report describing a large U.S. home-care platform focused on sleep, respiratory, diabetes and broader wellness-at-home products and services. The company operates four segments and, as of December 31, 2025, served about 4.3 million patients through roughly 640 locations in 48 states.
Revenue is diversified across resupply and one-time sales (about 63% of 2025 net revenue), monthly rental equipment (about 33%) and at-risk capitation contracts (about 4%). The report highlights reliance on a few key suppliers, heavy exposure to Medicare, Medicaid and private payors, significant regulatory and reimbursement uncertainty, cybersecurity and AI-related risks, inflation and labor pressures, and potential impacts from new U.S. health and climate-related laws.
AdaptHealth Corp. reported essentially flat 2025 sales but a swing to loss and outlined higher 2026 targets. Net revenue for 2025 was $3,244.9 million, down 0.5%, while net loss attributable to AdaptHealth was $70.8 million versus prior-year net income of $90.4 million, driven in part by a $128.0 million non-cash goodwill impairment in the Diabetes Health unit. Adjusted EBITDA fell 10.5% to $616.7 million, and fourth quarter Adjusted EBITDA declined 18.7% to $163.1 million, including a $14.5 million legal settlement expense and over $10 million of strategic investments. Cash flow from operations remained strong at $601.8 million, up from $541.8 million, with full-year free cash flow of $219.4 million. The company reduced debt by $250 million in 2025 and received credit upgrades from S&P and Moody’s. For 2026, AdaptHealth guides to net revenue of $3.44–$3.51 billion, Adjusted EBITDA of $680–$730 million, and free cash flow of $175–$225 million, reflecting expectations for improved profitability after a transition year.
FMR LLC and Abigail P. Johnson report beneficial ownership of 7,631,435.08 shares of AdaptHealth Corp common stock, representing 5.6% of the class as of 12/31/2025. FMR has sole voting power over 7,626,717 shares and sole dispositive power over 7,631,435.08 shares.
The filing states the shares were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control of AdaptHealth. One or more other persons may receive dividends or sale proceeds, but no such person holds more than five percent of the outstanding common stock.
AdaptHealth Corp.'s Chief Legal Officer and General Counsel, Richard W. Rew II, reported an equity award of 53,688 shares of common stock on January 30, 2026, coded as an acquisition. The filing shows these shares as restricted stock units that will be settled in common stock when they vest.
After this grant, Rew beneficially owned a total of 102,097 shares of AdaptHealth common stock in direct ownership, reflecting his updated equity stake as a senior officer.
AdaptHealth Corp.’s Chief Commercial Officer Russell E. Schuster III reported an equity award of 48,807 shares of common stock on 01/30/2026. The Form 4 shows the transaction coded as an acquisition at a reported price of $0.00 per share, indicating a stock-based grant.
A footnote explains these 48,807 shares are restricted stock units that will be settled in common stock upon vesting. After this award, Schuster beneficially owns 147,813 shares of AdaptHealth common stock in direct form.
AdaptHealth Corp.'s Chief Operating Officer, Toby Scott Barnhart, received a grant of restricted stock units (RSUs). On 01/30/2026, he was awarded 68,330 shares of common stock at a price of $0 per share, classified as an acquisition.
These RSUs will be settled in AdaptHealth common stock upon vesting, meaning the shares are delivered over time as conditions are met. Following this grant, Barnhart beneficially owns 220,654 shares of AdaptHealth common stock in direct ownership.